How a 25-Cent Pill Became a Hundred-Billion-Dollar Business

2026-06-11 · 41 min · 7 entities

episode page audio

Asserted relationships

→ discusses Society & Culture concept

0.40

evidence rules-v5
Feed category: Society & Culture
→ discusses News concept

0.40

evidence rules-v5
Feed category: News
→ discusses Documentary concept

0.40

evidence rules-v5
Feed category: Documentary
→ hosted by ProPublica company

0.40

evidence rules-v5
Feed author/publisher: ProPublica

Entities found in this episode

concepts 5

mentioned Society & Culture concept

0.50

evidence rules-v5
Feed category: Society & Culture
mentioned Documentary concept

0.50

evidence rules-v5
Feed category: Documentary
discusses Society & Culture concept

0.40

evidence rules-v5
Feed category: Society & Culture
discusses News concept

0.40

evidence rules-v5
Feed category: News
discusses Documentary concept

0.40

evidence rules-v5
Feed category: Documentary

companys 2

mentioned ProPublica company

0.70

evidence rules-v5
Feed author/publisher: ProPublica
hosted by ProPublica company

0.40

evidence rules-v5
Feed author/publisher: ProPublica

Episode description as stored

Reporter David Armstrong was diagnosed with cancer and soon learned that one of his drugs would cost almost $1,000 per pill. He set out to discover why, and uncovered financial records and legal filings that shocked him. The drugmaker’s strategy to raise the price over and over again helps explain why our healthcare system is the most expensive in the world. Read the original reporting: https://www.propublica.org/article/revlimid-price-cancer-celgene-drugs-fda-multiple-myeloma Support our journalism by donating at propublica.org/donate .